Published in Health and Medicine Week, July 26th, 2004
The new board will include Vincent E. Low, a New York-based executive who has been active in biotechnology, real estate, and hospitality companies and has been involved in five public offerings to date.
The merger will combine IsoRay Inc.; IsoRay Management, LLC; and IsoRay Products, LLC into one corporate entity as the company readies for the introduction of its new U.S. Food and Drug Administration (FDA)-approved Cesium-131 brachytherapy seed, stated IsoRay's chief executive officer Roger...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week